| Phase 3 |
| NCT04803994 |
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization… |
Hepatocellular Carcinoma |
Recruiting |
2025-01-07 |
| Phase 2 |
| NCT07110038 |
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab… |
Penile Squamous Cell Carcinoma (PSCC) |
Recruiting |
2026-10-13 |
| NCT07260175 |
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in… |
Cholangiocarcinoma |
Recruiting |
2026-08-12 |
| NCT07176312 |
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive… |
Gastroesophageal Adenocarcinoma |
Recruiting |
2026-06-30 |
| NCT07387198 |
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab |
Merkel Cell Carcinoma, Stage I |
Recruiting |
2026-06-22 |
| NCT06981325 |
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced… |
Basal Cell Carcinoma (BCC) |
Recruiting |
2026-03-11 |
| NCT06722183 |
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid… |
Colorectal Cancer |
Recruiting |
2025-12-24 |
| NCT06856837 |
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in… |
Metastatic Colorectal Cancer |
Recruiting |
2025-12-12 |
| NCT06440993 |
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic… |
Extrahepatic Cholangiocarcinoma |
Recruiting |
2025-12-01 |
| NCT06207734 |
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2… |
Breast Cancer |
Recruiting |
2025-05-01 |
| NCT05713838 |
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation… |
Esophagus Adenocarcinoma |
Active, Not Recruiting |
2026-08-07 |
| NCT04522544 |
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC |
Hepatocellular Carcinoma Non-resectable |
Active, Not Recruiting |
2026-06-23 |
| NCT05825625 |
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing |
Non-small Cell Lung Cancer |
Active, Not Recruiting |
2026-06-23 |
| NCT07542678 |
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell… |
Relapsed /Refractory DLBCL |
Not Yet Recruiting |
2026-04-21 |
| NCT05798156 |
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With… |
Lymphoma, Large B-Cell, Diffuse |
Active, Not Recruiting |
2026-04-08 |
| NCT07507968 |
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal… |
Esophagogastric Adenocarcinoma |
Not Yet Recruiting |
2026-04-02 |
| NCT06178445 |
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated… |
Biliary Tract Cancer |
Active, Not Recruiting |
2026-03-27 |
| NCT06680622 |
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the… |
Metastatic Gastro-esophageal Adenocarcinoma |
Active, Not Recruiting |
2026-01-07 |
| NCT04238637 |
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary… |
Intrahepatic Cholangiocarcinoma |
Active, Not Recruiting |
2025-12-05 |
| NCT05174650 |
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2… |
Intrahepatic Cholangiocarcinoma |
Active, Not Recruiting |
2025-12-05 |
| NCT03421288 |
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune… |
Gastric Cancer |
Active, Not Recruiting |
2025-07-25 |
| Phase 1/2 |
| NCT06731803 |
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing… |
Esophagogastric Adenocarcinoma |
Active, Not Recruiting |
2026-04-21 |
| Phase 1 |
| NCT07059299 |
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of… |
Esophagogastric Junction Adenocarcinoma |
Recruiting |
2025-12-19 |
| NCT03252938 |
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors |
Solid Tumors |
Active, Not Recruiting |
2026-02-19 |
| Not specified |
| NCT07510724 |
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint… |
Small Cell Lung Cancer (SCLC) |
Recruiting |
2026-04-03 |